Benadryl for infants
This article was originally published in The Tan Sheet
Only one in 22 infants who were given Pfizer's Benadryl (diphenhydramine) to aid with sleep saw an improvement in their condition compared to three of 22 infants taking placebo, a study in the July Archives of Pediatrics & Adolescene Medicine finds. Dan Merenstein, MD, Johns Hopkins University, et al., conducted a double-blind, randomized, controlled clinical trial of the 44 children, ages 6 months to 15 months. Placebo or diphenhydramine was given to the babies 30 minutes before anticipated bed time. Parents reported on the number of night awakenings requiring parental assistance during a week of drug treatment and 2-4 weeks after its discontinuation. Secondary outcomes included parental overall happiness with sleep and improved sleep latency. The data safety monitoring board voted unanimously to stop the trial because of lack of effectiveness of diphenhydramine over placebo...
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.